Acute rejection is a known risk factor for developing @entity740 , which remains as a major cause of long-term graft loss. Daclizumab (Zenapax), a humanized anti @entity2902 ( @entity2902 ) alpha monoclonal antibody, is a novel selective immunosuppressive agent for the prophylaxis of acute rejection. Six @entity1 (aged from 32 to 48) after cadaver and living donor kidney transplantation (Tx) have been treated with Daclizumab since 2000 in Lithuania. Daclizumab was prescribed (1.0 mg/kg intravenously before Tx and once every other week afterwards (five dozes in total) for all @entity1 , except one, who received two dozes. The induction therapy was administered due to various immunological risk factors: retransplantated, sensitized and poorly HLA-matched @entity1 , as well as non-immunological risk factors such as @entity1 with @entity6 , with kidney from sub-optimal donors, @entity28 of @entity1 , etc. The maintenance immunosuppression consisted of @entity205 , @entity618 and prednisolon in all @entity1 except one, who was treated without @entity230 . All the @entity1 have been folloved-up for 5-36 months. Within the observation period in early time after Tx all the @entity1 are alive and have no clinical signs of rejection. The graft function is normal (serum creatinine ranges between 100-120 micromol/l). CONCLUSION: Induction therapy with Daclizumab is safe and efficacious in preventing acute rejection in high risk kidney recipients.

[Anti XXXX antibodies (daclizumab) application for the treatment of kidney recipients].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic allograft nephropathy'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity2902 :: ('3559', 'Gene') :: ['IL-2R', 'interleukin-2 receptor'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']
@entity2902 :: (3559,Gene) :: ['interleukin-2 receptor alpha']
